ClinicalTrials.gg
RecruitingNCT03957902Updated Feb 27, 2025

Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer

A Phase 2 interventional study of acetylsalicylic acid in Colorectal Cancer, sponsored by Instituto de Investigación Sanitaria Aragón. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2025-02-27.

Sponsored by Instituto de Investigación Sanitaria Aragón · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started May 2019; still recruiting 7 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing aspirin in Colorectal Neoplasms — 1 open to participants now, 9 under way, 5 of them phase 3. Aspirin · Colorectal Neoplasms.

Planned enrollment
16th of 22
60 · median 161
Started
2019
the only one that year
Phase 2
7 of 22
1 open now
Registered
17th of 22
by date
Lead sponsor
1 of 22
Instituto de Investigación Sanitaria Aragón

Among the 22 studies testing aspirin in Colorectal Neoplasms, this one is the 16th largest by planned enrollment, is the only one that started in 2019, is one of 7 in phase 2, and was the 17th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 22 studies testing aspirin in Colorectal Neoplasms is open now, in 1 country.

By country, each count listing its studies:

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing aspirin in Colorectal Neoplasms, or all of them as a file.
02

Study summary

Acetylsalicylic acid (ASA) seems the ideal colorectal cancer (CRC) chemoprevention agent. Several ongoing trials are testing the effect of ASA as co-therapy in CRC. The mechanisms of action, the appropriate dose and the ideal target population are unknown. The investigators have demonstrated that doses of 100 mg of ASA induce direct and partial but persistent acetylation of the cyclooxygenase (COX) isoenzyme COX-1 in the normal colorectal mucosa. The primary objective is to perform a study of aspirin by using a proteomic assay for comparing platelet COX-1 and CRC mucosal COX-1 after different doses of ASA. Secondary objectives are: the measurement of prostaglandin E2 (PGE2) and phosphorylated S6 protein (p-S6) levels in CRC mucosa, the assessment of indirect biomarker of aspirin action (serum thromboxane B2 (TXB2) and urinary levels of 11-dehydro-TXB2 (TX-M)), the evaluation of systemic biomarkers of inflammatory/tumorigenic COX-2 by assessing urinary levels of major metabolite of PGE2 (PGE-M). Methods: Phase II randomized clinical trial in 60 patients with newly diagnosed CRC in 3 groups of 20 patients receiving 100 or 300 mg/day, or 100 mg/12 hours of enteric-coated ASA for 3±1 weeks, prior to definitive treatment by surgery. Main outcome: Acetylation of COX-1 and COX-2. Eicosanoid levels in target organs. Expected results: Evidence for the current uncertainty about the mechanisms of action and the dose required to obtain the best chemopreventive effect with ASA in CRC. Confirm acetylation of COX as a key biomarker of efficacy with ASA.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age ≥ 18 \< 80 years old
  • recent diagnosis (\< 48h) of rectum or colon cancer, established by endoscopy and later confirmed by anatomo-pathologic study
  • normal coagulation values and biochemical vales without deviations that, at the discretion of the investigator, may interfere with the study procedures

Exclusion criteria

Exclusion Criteria:

  • Allergy to ASA or to any other NSAID.
  • Rectal cancer requiring treatment within the two weeks following the beginning of ASA treatment.
  • Previous use of ASA, NSAIDs, antiplatelet agents, or misoprostol within the 15 days prior to diagnosis and/or anticipation of need for treatment with any of these drugs during the study period. History of peptic ulcer disease or active peptic ulcer or any other gastrointestinal disease that may be considered a to the use of ASA, without the concomitant use of proton pump inhibitors.
  • Diagnosis of bleeding disorders.
  • Diagnosis of cancer (excluding non-melanoma skin cancer) within the previous 3 years.
  • Conditions supposing serious comorbidity, excluding diabetes, and including respiratory, cardiac, hepatic and renal diseases.
  • Active smoking.
  • Pregnancy or breastfeeding.
  • History of drug or alcohol abuse.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Arm 1 (100 mg/24h)

    Drug: acetylsalicylic acid

  • Experimental
    Arm 2 (300 mg/24h)

    Drug: acetylsalicylic acid

  • Experimental
    Arm 3 (100 mg/12h)

    Drug: acetylsalicylic acid

Interventions

  • DrugAspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Different dosage effect over platelet COX enzymes, non- neoplastic and neoplastic colonic tissues used as biomarkers of clinical efficacy in CRC chemoprevention

06

What researchers measure

Primary outcomes

  1. Assessment of changes in acetylation levels of COX enzymes in platelets and non-neoplastic and neoplastic colonic tissues

    Time frame: before the beginning of the treatment and 3 ± 1 weeks of acetylsalicylic acid treatment

Secondary outcomes

  1. Assessment of changes in prostaglandin E2 (PGE2) levels in colorectal mucosa depending on drug dosis

    Time frame: before the beginning of the treatment and 3 ± 1 weeks of acetylsalicylic acid treatment

  2. Assessment of changes in phosphorylated S6 protein (p-S6) levels in colorectal mucosa depending on drug dosis

    Time frame: before the beginning of the treatment and 3 ± 1 weeks of acetylsalicylic acid treatment

  3. Assessment of changes in thromboxane B2 (TxB2) levels in urine as indirect systemic biomarker depending on drug dosis

    Time frame: before the beginning of the treatment and 3 ± 1 weeks of acetylsalicylic acid treatment

  4. Assessment of changes in urinary metabolite 11-dehydro-TxB2 (TX-M) levels as indirect systemic biomarker depending on drug dosis

    Time frame: before the beginning of the treatment and 3 ± 1 weeks of acetylsalicylic acid treatment

  5. Assessment of changes in major urinary metabolite of PGE2 (PEG-M) levels depending on drug dosis

    Time frame: before the beginning of the treatment and 3 ± 1 weeks of acetylsalicylic acid treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2019 (actual). Primary completion is estimated for May 2025, 72 months after the start.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 72 months is above that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2019
First posted
May 21, 2019
StartActual
May 6, 2019
Primary completionEst.
May 2025
CompletionEst.
Jun 2025
Last update
Feb 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03957902
Lead sponsor
Instituto de Investigación Sanitaria Aragón
Collaborators
Instituto de Salud Carlos III, G. d'Annunzio University, Hospital Clínico Universitario Lozano Blesa
Responsible party
Ángel Lanas Arbeloa (Head of Digestive Diseases Service, Instituto de Investigación Sanitaria Aragón) — Principal investigator
First posted
May 21, 2019
Start date
May 6, 2019
Primary completion
May 2025 (estimated)
Completion
Jun 2025 (estimated)
Last update
Feb 27, 2025

Study contacts

Ángel Lanas Arbeloa, MD
Contact
angel.lanas@gmail.com
0034976765786
Ángel Lanas Arbeloa, MD
principal investigator · Instituto de Investigación Sanitaria Aragón

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion